<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35765080</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1172</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Orphanet journal of rare diseases</Title><ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in Fabry disease: a reference center prospective study.</ArticleTitle><Pagination><StartPage>250</StartPage><MedlinePgn>250</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">250</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-022-02386-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">During the coronavirus disease-19 (COVID-19) pandemic, vulnerable populations must be identified to prevent increased mortality. Fabry disease (FD) is a rare X-linked lysosomal storage disorder leading to chronic kidney disease (CKD), cardiomyopathy, pneumonopathy and premature strokes. Little is known whether SARS-CoV-2 infection bears a particular risk for FD patients.</AbstractText><AbstractText Label="METHODS">During pandemic (02.2020-03.2021) we have regularly followed 104 unvaccinated FD patients. In 61/104, titre of serum antibodies against SARS-CoV-2 were measured and SARS-CoV-2 PCR test was performed in symptomatic patients or in case of positivity of other family members. The symptoms and duration of COVID-19 were reported by the patients or the treating physician.</AbstractText><AbstractText Label="RESULTS">No deaths or intensive care unit hospitalizations occurred. 13/104 (12.5%) were diagnosed with SARS-CoV-2 infection (16.7% (4/24) men 12.2% (6/49) women of classic phenotype, 25% (3/12) of the men and 0% (0/8) of the women of later- onset phenotype). Of those, 2/13 (15.4%) patients-both kidney transplant recipients-developed severe COVID-19, were hospitalized, and required a high-flow oxygen mask. The rest either developed mild COVID-19 manifestations (8/13, 61.5%) or were asymptomatic (3/13, 23.1%). 2/13 (15.4%) of the patients experienced Fabry pain crisis and 3/13 (23.1%) long COVID-19 like symptoms.</AbstractText><AbstractText Label="CONCLUSIONS">Similar to the general population, in FD patients the risk for severe COVID-19 seems to be driven by the immune system rather than by FD itself. Immunosuppression in kidney transplant recipients represented the highest risk in this population.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bothou</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), R&#xe4;mistrasse 100, 8091, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Lanja</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Eckardstein</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuschlein</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), R&#xe4;mistrasse 100, 8091, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Albina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4119-5516</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), R&#xe4;mistrasse 100, 8091, Zurich, Switzerland. albina.nowak@usz.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Psychiatry University Hospital Zurich, Zurich, Switzerland. albina.nowak@usz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Orphanet J Rare Dis</MedlineTA><NlmUniqueID>101266602</NlmUniqueID><ISSNLinking>1750-1172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000795" MajorTopicYN="Y">Fabry Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">Fabry disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Antibody Titer</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35765080</ArticleId><ArticleId IdType="pmc">PMC9237963</ArticleId><ArticleId IdType="doi">10.1186/s13023-022-02386-7</ArticleId><ArticleId IdType="pii">10.1186/s13023-022-02386-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46&#x2013;64. doi: 10.1038/s41581-020-00357-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-00357-4</ArticleId><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123(2):148&#x2013;153. doi: 10.1016/j.ymgme.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2017.07.002</ArticleId><ArticleId IdType="pubmed">28728877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236&#x2013;242. doi: 10.1111/j.1365-2362.2004.01309.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2004.01309.x</ArticleId><ArticleId IdType="pubmed">15025684</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak A, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. J Inherit Metab Dis. 2020;43(2):326&#x2013;333. doi: 10.1002/jimd.12167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jimd.12167</ArticleId><ArticleId IdType="pubmed">31449323</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martinez D, Aguiar P, Auray-Blais C, Beck M, Bichet DG, Burlina A, et al. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: a global Delphi consensus. Mol Genet Metab. 2021;132(4):234&#x2013;243. doi: 10.1016/j.ymgme.2021.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2021.02.001</ArticleId><ArticleId IdType="pubmed">33642210</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J Am Soc Nephrol. 2017;28(5):1631&#x2013;1641. doi: 10.1681/ASN.2016090964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016090964</ArticleId><ArticleId IdType="pmc">PMC5407735</ArticleId><ArticleId IdType="pubmed">27979989</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira JP, Ferreira S. Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype-phenotype correlations. Appl Clin Genet. 2019;12:35&#x2013;50. doi: 10.2147/TACG.S146022.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TACG.S146022</ArticleId><ArticleId IdType="pmc">PMC6407513</ArticleId><ArticleId IdType="pubmed">30881085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189&#x2013;203. doi: 10.1016/j.ymgme.2018.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2018.06.004</ArticleId><ArticleId IdType="pubmed">30017653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner C, Feldt-Rasmussen U, Jovanovic A, Linhart A, Yang M, Ponce E, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail. 2020;7(3):825&#x2013;834. doi: 10.1002/ehf2.12647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12647</ArticleId><ArticleId IdType="pmc">PMC7261571</ArticleId><ArticleId IdType="pubmed">32100468</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365982</ArticleId><ArticleId IdType="pubmed">30775256</ArticleId></ArticleIdList></Reference><Reference><Citation>Laney DA, Germain DP, Oliveira JP, Burlina AP, Cabrera GH, Hong GR, et al. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. Clin Kidney J. 2020;13(6):913&#x2013;925. doi: 10.1093/ckj/sfaa227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfaa227</ArticleId><ArticleId IdType="pmc">PMC7769541</ArticleId><ArticleId IdType="pubmed">33391734</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Spectrum of SARS-CoV-2 Infection [Internet]. 2020.</Citation></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>People with Certain Medical Conditions [Internet]. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. 2020.</Citation></Reference><Reference><Citation>Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790&#x2013;796. doi: 10.1097/GIM.0b013e3181bb05bb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e3181bb05bb</ArticleId><ArticleId IdType="pubmed">19745746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med. 1997;155(3):1004&#x2013;1010. doi: 10.1164/ajrccm.155.3.9116979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.155.3.9116979</ArticleId><ArticleId IdType="pubmed">9116979</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzen D, Haile SR, Kasper DC, Mechtler TP, Flammer AJ, Krayenbuhl PA, et al. Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy. BMJ Open Respir Res. 2018;5(1):e000277. doi: 10.1136/bmjresp-2018-000277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2018-000277</ArticleId><ArticleId IdType="pmc">PMC5922571</ArticleId><ArticleId IdType="pubmed">29713479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: molecular and structural insights. J Basic Microbiol. 2021;61(3):180&#x2013;202. doi: 10.1002/jobm.202000537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jobm.202000537</ArticleId><ArticleId IdType="pmc">PMC8013332</ArticleId><ArticleId IdType="pubmed">33460172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechi A, Macor D, Valent S, Da Riol RM, Zanatta M, Spinelli A, et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab. 2020;130(3):170&#x2013;171. doi: 10.1016/j.ymgme.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7189198</ArticleId><ArticleId IdType="pubmed">32386848</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccio E, Pieroni M, Limoneglli G, Pisani A. Impact of COVID-19 pandemic on patients with Fabry disease: an Italian experience. Mol Genet Metab. 2020;131(1&#x2013;2):124&#x2013;125. doi: 10.1016/j.ymgme.2020.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2020.07.008</ArticleId><ArticleId IdType="pmc">PMC7386205</ArticleId><ArticleId IdType="pubmed">32741663</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312&#x2013;320. doi: 10.1136/postgradmedj-2020-138577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138577</ArticleId><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Lujan M, Cruzalegui C, Aguilar C, Alvarez-Vargas M, Segura-Saldana P. When Frequent (Pandemic) Occurs in a Non-Frequent Disease: Covid-19 and Fabry Disease: Report of Two Cases. Jpn J Infect Dis. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33250492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M, et al. beta-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020;183(6):1520-+.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590812</ArticleId><ArticleId IdType="pubmed">33157038</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Tsai SJ, Ai Y, Li M, Pekosz A, Cox A, et al. The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike. bioRxiv. 2020.</Citation></Reference><Reference><Citation>Franzen DP, Nowak A, Haile SR, Mottet D, Bonani M, Dormond O, et al. Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. PLoS ONE. 2017;12(7):e0180437. doi: 10.1371/journal.pone.0180437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180437</ArticleId><ArticleId IdType="pmc">PMC5526574</ArticleId><ArticleId IdType="pubmed">28742806</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisin RC, Rozenfeld P, Bonardo P. Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. Med Hypotheses. 2020;144:110282. doi: 10.1016/j.mehy.2020.110282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110282</ArticleId><ArticleId IdType="pmc">PMC7494494</ArticleId><ArticleId IdType="pubmed">33254586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Lujan M, Cruzalegui C, Aguilar C, Alvarez-Vargas M, Segura-Saldana P. When Frequent (Pandemic) Occurs in a Non-Frequent Disease: COVID-19 and Fabry Disease: Report of Two Cases. Jpn J Infect Dis. 2021;74(3):228&#x2013;232. doi: 10.7883/yoken.JJID.2020.729.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2020.729</ArticleId><ArticleId IdType="pubmed">33250492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney R, Lee GK, Zepeda JP, Gabriel C, Hall K, Edwards R, et al. Severe manifestations and treatment of COVID-19 in a transplanted patient with Fabry disease. Mol Genet Metab Rep. 2021;29:100802. doi: 10.1016/j.ymgmr.2021.100802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgmr.2021.100802</ArticleId><ArticleId IdType="pmc">PMC8443332</ArticleId><ArticleId IdType="pubmed">34545322</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. 2020;20(4):229&#x2013;238. doi: 10.1038/s41577-019-0244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0244-2</ArticleId><ArticleId IdType="pmc">PMC7223087</ArticleId><ArticleId IdType="pubmed">31836872</ArticleId></ArticleIdList></Reference><Reference><Citation>Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153&#x2013;2158. doi: 10.1681/ASN.2021040490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021040490</ArticleId><ArticleId IdType="pmc">PMC8729854</ArticleId><ArticleId IdType="pubmed">34135083</ArticleId></ArticleIdList></Reference><Reference><Citation>Miele M, Busa R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant. 2021;21(8):2919&#x2013;2921. doi: 10.1111/ajt.16702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16702</ArticleId><ArticleId IdType="pmc">PMC8222937</ArticleId><ArticleId IdType="pubmed">34058052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244&#x2013;1246. doi: 10.1056/NEJMc2111462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2111462</ArticleId><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M, Thomson T, Clarke CL, Martin P, Gleeson S, De Aguiar RC, et al. Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. Lancet. 2021;398(10310):1482&#x2013;1484. doi: 10.1016/S0140-6736(21)02096-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02096-1</ArticleId><ArticleId IdType="pmc">PMC8489877</ArticleId><ArticleId IdType="pubmed">34619100</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>